Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
type
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member

Search

1762649

	registered interest
	date	05/02/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Supermarkets: Nutrition
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of introducing mandatory healthiness targets for large supermarket retailers.
	tabling member constituency	North Devon
	tabling member printed	Ian Roome
	type	WrittenParliamentaryQuestion
	uin	29338
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>The Government is committed to raising the healthiest generation of children and tackling the three biggest killers which will require effort from across society on not just obesity but alcohol and smoking. We have made a start with Tobacco and Vapes Bill and will continue to speak to partners across industry and civic society to best understand what actions help to change behaviours in a way that puts power in the hands of consumers.</p><p>As part of the Government’s Plan for Change, we are committed to achieving our health mission to build a National Health Service fit for the future, and under the 10-Year Health Plan to shift from ‘sickness to prevention’. Making the healthier choice the easier choice is a major part of creating a food environment that is fairer, with the fewest lives lost to the biggest killers and where everyone lives well for longer. Obesity is one of the key drivers of ill health, economic inactivity and premature mortality, as highlighted in the recently published Get Britain Working White Paper.</p><p>As part of considerations around mandatory healthiness targets, the Food Data Transparency Partnership (FDTP) was created prior to the 2024 General Election; this was a shared programme of work across the Department of Health and Social Care, the Department for Environment, Food, and Rural Affairs, and the Food Standards Agency. The FDTP was paused at the election and is being reviewed alongside other obesity policies.</p> answering member constituency West Lancashire answering member printed Ashley Dalton question first answered 17/03/2025 11:26:01 answering member 4981 label Biography information for Ashley Dalton
	tabling member	5138

1778290

	registered interest
	date	25/02/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Obesity: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an estimate of the number of deaths caused by weight-loss drugs in each of the last five years.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	type	WrittenParliamentaryQuestion
	uin	33552
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available data, including from the Yellow Card scheme, and seeks advice from their independent advisory committee, the Commission on Human Medicines, where appropriate to inform regulatory decisions.</p><p>Patient safety is our top priority, and no medicine would be approved unless it met our expected standards of safety, quality and effectiveness. Our role is to continually monitor the safety of medicines during their use, including GLP-1 receptor agonists (RAs). We have robust, safety monitoring and surveillance systems in place for all healthcare products.  When a safety issue is confirmed, we always act promptly to inform patients and healthcare professionals and take appropriate steps to mitigate any identified risk. New medicines, such as GLP-1 RAs, are more intensively monitored to ensure that any new safety issues are identified promptly.</p><p>It is important to note that a reaction reported to the Yellow Card scheme does not necessarily mean it has been caused by the medicine, only that the reporter had a suspicion it may have<em>.</em> Underlying or concurrent illnesses may be responsible, or the events could be coincidental.</p><p>Based on the current evidence, the benefits of GLP-1 RAs outweigh the potential risks when used for the licensed indications. The decision to start, continue or stop treatments should be made jointly by patients and their doctor, based on full consideration of the benefits and risks. We strongly encourage patients and healthcare professionals to continue reporting suspected side effects to GLP-1 RAs through our Yellow Card scheme.</p><p>The following table shows the number of Yellow Card reports received for each GLP1 RA with a fatal outcome up to and including 31 January 2025, along with the number of these which were reported with an indication relating to weight management:</p><table><tbody><tr><td><p>GLP1 RA</p></td><td><p>Number of reports with a fatal outcome (of which include an indication relating to weight management)</p></td></tr><tr><td><p>Semaglutide</p></td><td><p>29 (4)</p></td></tr><tr><td><p>Liraglutide</p></td><td><p>35 (8)</p></td></tr><tr><td><p>Tirzepatide</p></td><td><p>18 (10)</p></td></tr></tbody></table><p>Source: MHRA database</p><p>As the use of the GLP-1 RAs increases, so have the number of Yellow Card reports associated with these medicines. Yellow Card reporting rates can be influenced by many factors including the seriousness of the adverse drug reactions, their ease of recognition and the extent of use of a particular product. Reporting can also be stimulated by publicity and awareness about a product.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 17/03/2025 09:27:25 answering member 4444 label Biography information for Karin Smyth
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1778698

	registered interest
	date	26/02/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with his counterpart in the Northern Ireland Executive on lowering the threshold for bowel screening to 50.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	type	WrittenParliamentaryQuestion
	uin	33884
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>The UK National Screening Committee (UK NSC) advises ministers and the National Health Service in the four United Kingdom nations about all aspects of screening. As screening is a devolved matter, it is then for each individual Government to decide on how and whether to implement the UK NSC’s recommendations.</p> answering member constituency West Lancashire answering member printed Ashley Dalton question first answered 17/03/2025 12:00:17 answering member 4981 label Biography information for Ashley Dalton
	tabling member	4131 label Biography information for Jim Shannon

1778913

	registered interest
	date	26/02/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Arthritis and Musculoskeletal Disorders: Ethnic Groups
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help reduce health disparities amongst ethnic minority communities in the treatment of (a) arthritis and (b) musculoskeletal conditions.
	tabling member constituency	North Herefordshire
	tabling member printed	Ellie Chowns
	type	WrittenParliamentaryQuestion
	uin	34128
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>The Race Equality Foundation’s report, Musculoskeletal conditions and Black, Asian and minority ethnic people: addressing health inequalities, commissioned by what was then Public Health England, identified that some Black, Asian and minority ethnic groups in the United Kingdom are disproportionately represented due to the risk factors for musculoskeletal (MSK) conditions. MSK pain is more widespread among people in minority ethnic groups that may reflect social, cultural and psychological differences. The report is available at the following link:</p><p><a href="https://raceequalityfoundation.org.uk/health-and-care/musculoskeletal-conditions-and-black-asian-and-minority-ethnic-people-addressing-health-inequalities/" target="_blank">https://raceequalityfoundation.org.uk/health-and-care/musculoskeletal-conditions-and-black-asian-and-minority-ethnic-people-addressing-health-inequalities/</a></p><p>We have set a Health Mission with the aim of tackling the social determinants of health such as those described in the report, focusing on prevention, and ensuring that everyone lives longer, healthier lives. We have also committed to delivering a 10-Year Health Plan, which will set out a bold agenda to deliver on the three big shifts needed, to move healthcare from the hospital to the community, from analogue to digital, and from treatment to prevention. Addressing healthcare inequity is a core focus of the 10-Year Health Plan, including for people from minority ethnic groups.</p><p>Integrated care boards (ICBs) are responsible for commissioning services that meet the needs of their local population, including for MSK conditions such as arthritis. Under the Health and Care Act 2022, ICBs have a duty to consider reducing inequalities with respect to people’s ability to access services within the National Health Service and the outcomes achieved for them by the provision of those health services, including for people from ethnic minority backgrounds.</p> answering member constituency West Lancashire answering member printed Ashley Dalton question first answered 17/03/2025 11:29:10 answering member 4981 label Biography information for Ashley Dalton
	tabling member	5249

1779051

	registered interest
	date	26/02/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many yellow card reports on covid-19 vaccines there were in 2024.
	tabling member constituency	Great Yarmouth
	tabling member printed	Rupert Lowe
	type	WrittenParliamentaryQuestion
	uin	34093
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusion meet the applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses the available data, including from the Yellow Card scheme, and seeks advice from the Commission on Human Medicines, the MHRA’s independent advisory committee, where appropriate, to inform regulatory decisions, which includes amending the product information.</p><p>All COVID-19 vaccines used in the United Kingdom have been authorised by the MHRA after meeting the MHRA’s standards of safety, quality, and effectiveness. As with all vaccines and medicines, the safety of COVID-19 vaccines is continuously monitored, and benefits and possible risks remain under review. The MHRA has received a total of 6,912 spontaneous suspected side effects to COVID-19 vaccines in 2024 from over 15 million doses estimated to have been administered across the UK.</p><p>When considering the above spontaneous data, it is important to be aware that a reported reaction does not necessarily mean it has been caused by the vaccine, medicine, or device, only that the reporter had a suspicion it may have been. The fact that the symptoms reported to the Yellow Card scheme occur after the use of a vaccine, medicine, or device does not in itself mean that they are proven to have been caused by it. Underlying or concurrent illnesses may be responsible, and such events can also be coincidental.</p><p>It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffered adverse reactions, and therefore they cannot be used to determine the incidence of a reaction or compare the safety profile of different vaccines, medicines, or devices. Adverse drug reactions and device incident reporting rates are influenced by the seriousness of the adverse reactions, their ease of recognition, and the extent of use of a particular medicine or device, and may also be stimulated by promotion and publicity. Reporting tends to be highest for newly introduced medicines during the first one to two years on the market, and then falls over time.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 17/03/2025 10:00:00 answering member 4444 label Biography information for Karin Smyth
	tabling member	5158

1780407

	registered interest
	date	03/03/2025
	answering body	Foreign, Commonwealth and Development Office
	answering dept id	208
	answering dept short name	Foreign, Commonwealth and Development Office
	answering dept sort name	Foreign, Commonwealth and Development Office
	hansard heading	Israel: Syria
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what his Department's policy is on the presence of Israeli armed forces in positions within Syria since 8 December 2024.
	tabling member constituency	Dundee Central
	tabling member printed	Chris Law
	type	WrittenParliamentaryQuestion
	uin	34857
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>We continue to call on Israel, and all actors, to uphold their obligations to peace, stability, and security under international law.  We are increasingly concerned by Israel's actions in Syria and are raising these concerns directly with the Israeli authorities. Israel have said their presence in the buffer zone in the Golan Heights will be limited and temporary, and we have been clear that we expect them to adhere to this commitment. We recognise current threats to Israel, Israel's presence in the buffer zone must not become permanent.</p> answering member constituency Lincoln answering member printed Mr Hamish Falconer question first answered 17/03/2025 11:20:27 answering member 5148
	tabling member	4403 label Biography information for Chris Law

1780543

	registered interest
	date	03/03/2025
	answering body	Department for Transport
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Transport, what information her Department holds on the cost of a standard-class annual rail season ticket from (a) Eccles, (b) Moorside, (c) Patricroft and (d) Swinton to (i) Deansgate, (ii) Manchester Oxford Road, (iii) Manchester Piccadilly, and (iv) Manchester Victoria in 2010.
	tabling member constituency	Worsley and Eccles
	tabling member printed	Michael Wheeler
	type	WrittenParliamentaryQuestion
	uin	35098
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>The price of standard class annual season tickets in 2010 for journeys from the requested stations to these Manchester stations was £741.50.</p> answering member constituency Wakefield and Rothwell answering member printed Simon Lightwood question first answered 17/03/2025 09:50:36 answering member 4943 label Biography information for Simon Lightwood
	tabling member	5242

1780688

	registered interest
	date	03/03/2025
	answering body	Ministry of Justice
	answering dept id	54
	answering dept short name	Justice
	answering dept sort name	Justice
	hansard heading	Prisoners' Release
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government how many prisoners have been released early under the prisoner early release scheme since its introduction, broken down by offence category.
	tabling member printed	Lord Keen of Elie
	type	WrittenParliamentaryQuestion
	uin	HL5408
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>On 07 November, the Ministry of Justice published transparency data on how many offenders were released on the first days of Tranche 1 and Tranche 2 of SDS40 (1,889 prisoners on the first day of Tranche 1, and 1,223 prisoners on the first day of Tranche 2).</p><p>SDS40 is a legal requirement that applies to all prison institutions. Data on prison releases forms a subset of prison population data which is intended for future publication. In accordance with the requirements of the Code of Practice for Official Statistics, we may not give any early indication of the contents of this statistical report.</p> answering member printed Lord Timpson grouped question UIN HL5411 question first answered 17/03/2025 12:16:19 answering member 5364 label Biography information for Lord Timpson
	tabling member	4538 label Biography information for Lord Keen of Elie

1780691

	registered interest
	date	03/03/2025
	answering body	Ministry of Justice
	answering dept id	54
	answering dept short name	Justice
	answering dept sort name	Justice
	hansard heading	Prisoners' Release
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government whether they will publish (1) the names of all prisons participating in the prisoner early release scheme; and (2) the number of prisoners released from each institution.
	tabling member printed	Lord Keen of Elie
	type	WrittenParliamentaryQuestion
	uin	HL5411
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>On 07 November, the Ministry of Justice published transparency data on how many offenders were released on the first days of Tranche 1 and Tranche 2 of SDS40 (1,889 prisoners on the first day of Tranche 1, and 1,223 prisoners on the first day of Tranche 2).</p><p>SDS40 is a legal requirement that applies to all prison institutions. Data on prison releases forms a subset of prison population data which is intended for future publication. In accordance with the requirements of the Code of Practice for Official Statistics, we may not give any early indication of the contents of this statistical report.</p> answering member printed Lord Timpson grouped question UIN HL5408 question first answered 17/03/2025 12:16:19 answering member 5364 label Biography information for Lord Timpson
	tabling member	4538 label Biography information for Lord Keen of Elie

1781457

	registered interest
	date	05/03/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Children and Young People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what consideration his Department has given to including a separate faster diagnosis target for children and young people with cancer.
	tabling member constituency	Stroud
	tabling member printed	Dr Simon Opher
	type	WrittenParliamentaryQuestion
	uin	35791
	answer	answer is ministerial correction date of answer 17/03/2025 answer text <p>The Faster Diagnosis Standard (FDS) includes children and young people and ensures that cancer is diagnosed or ruled out, within 28 days from referral. The latest FDS data, for December 2024, shows that 89.8% of children and young people with suspected cancer received a diagnosis or all-clear within 28 days of referral, above the overall FDS rate.</p><p>We are committed to getting the National Health Service diagnosing cancer earlier and treating it faster so that more children and young people survive. That is why on 4 February 2025, we relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experience. The Taskforce will explore opportunities for improvement, including detection and diagnosis, genomic testing and treatment, research and innovation, and patient experience</p><p>The Taskforce will ensure that the unique needs of children and young people with cancer are carefully considered as part of the National Cancer Plan.</p> answering member constituency West Lancashire answering member printed Ashley Dalton question first answered 17/03/2025 11:21:31 answering member 4981 label Biography information for Ashley Dalton previous answer version 44806 answering member constituency West Lancashire answering member printed Ashley Dalton answering member 4981 label Biography information for Ashley Dalton
	tabling member	5030